Elicio Therapeutics, Inc ELTX 深 沪
等待开盘 08-10 09:30:00 美东时间
3.19
+0.050
+1.59%
华盛通- 最 高3.28
- 今 开3.20
- 成交量 12.14万股
- 最 低 2.87
- 昨 收 3.14
- 总市值 4.43万
- 52周最高 16.00
- 市盈率 静 --
- 换手率 874.87%
- 52周最低 2.66
- 委 比 39.62%
- 总股本 1.39万
- 历史最高 24.39
- 量 比 0.35
- 振 幅 13.06%
- 历史最低 1.10
- 每 手 1
- 风险率 2.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jones Trading Downgrades Elicio Therapeutics to Hold
Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
06-17 00:30
Elicio Therapeutics Pancreatic Cancer Study Disappoints
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.
06-16 00:29
Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial production up 0.1%. Housing market index declines to 35.
06-16 00:01
Dow Jumps Over 600 Points Following US-Iran Peace Deal
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.
06-15 22:08
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics is hosting a virtual KOL event on June 25 to discuss mutant-KRAS driven pancreatic cancer and its treatment. Experts will present insights on Elicio's AMP platform and ELI-002, a vaccine targeting KRAS mutations. A Q&A session will follow.
2025-06-17 12:00
Elicio Therapeutics Secures $10 Million in Financing
Elicio Therapeutics entered a $10 million senior secured promissory note with GKCC, LLC, which will support operations into Q1 2026 and cover the anticipated AMPLIFY-7P Phase 2 interim analysis in Q3 2025. The company aims to execute near-term initiatives and expand ELI-002 for various cancers.
2025-06-04 12:00
Elicio Therapeutics Announces 3 Upcoming Presentations Focused On Its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines In September And October.
Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced
2024-09-13 20:34
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $10 price target.
2024-08-23 20:06
